Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Genitourinary Cancer Channel

Explore the latest updates, including expert interviews and features

The GU Cancer Channel on VJOncology is supported by Exelixis These supporters have no influence over the production of the content.

Latest videos VJSessions Subtypes Topics Conferences Features Editorial Board

Welcome to the Genitourinary (GU) Cancer Channel!

Explore the latest updates presented at major international congresses in the form of video interviews, podcasts and roundtable discussions featuring members of our expert Editorial Board.

Exciting advances are being made in the field of genitourinary cancer, including checkpoint inhibitor treatments, new non-steroidal anti-androgens, chemoimmunotherapy combinations and predictive biomarkers.

GU Cancer Videos by Subtype

Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular Cancer
Penile Cancer
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
View All Videos
1:07
Developing targeted therapies for urachal and non-urachal adenocarcinoma
Antonio Cigliola • 26 Jan 2024
1:21
Genomic differences between urachal and non-urachal bladder adenocarcinoma
Antonio Cigliola • 26 Jan 2024
1:09
What role does FDG-PET have in managing bladder cancer?
Antonio Cigliola • 26 Jan 2024
1:06
Predicting pelvic lymph node involvement in MIBC with FDG-PET
Antonio Cigliola • 26 Jan 2024
View All Videos
2:52
LITESPARK-004: ESA use in VHL disease-associated RCC
Benjamin Maughan • 26 Jan 2024
3:04
Evaluating the role of radiotherapy in primary and metastatic RCC
Sophia Kamran • 26 Jan 2024
2:14
Managing renal cell carcinoma after progressing on checkpoint inhibitors
David Braun
1:24
The emerging benefits of adjuvant checkpoint inhibition in RCC
David Braun • 26 Jan 2024
View All Videos
1:39
Treatment outcomes in primary retroperitoneal germ-cell tumours
Patrizia Giannatempo • 26 Jan 2024
1:39
Can the ANZUP surveillance recommendations detect relapse in testicular cancer?
Ciara Conduit • 6 Jul 2023
1:18
CLIMATE: miR-371a-3p as a biomarker in post-orchiectomy testicular cancer
Ciara Conduit • 6 Jul 2023
2:14
The effects of post-RPLND retrograde ejaculation in men with testicular cancer
Ciara Conduit • 6 Jul 2023
View All Videos
6:51
Genitourinary cancer trials at ANZUP 2023: SUBDUE-1 and ZiPUP
Dickon Hayne • 26 Jun 2023
2:34
Supportive care requirements in patients with penile and prostate cancers
Haryana Dhillon • 17 Jul 2023
0:57
The evolving landscape of viral, immune and molecular biomarkers in penile cancer
Philippe Spiess • 10 Mar 2023
1:16
Predictors of response to surgery for penile cancer
Philippe Spiess • 10 Mar 2023
View All Videos

Topics

Trial Updates
Molecular Profiling
Immuno-Oncology
Diagnosis
Imaging
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
1:08
PSMA imaging pre- and post-177Lu-PSMA-617 treatment in mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:57
PROs in advanced cisplatin-ineligible UC: first-line EV ± pembrolizumab
Jonathan Rosenberg • 7 Apr 2024
View All Videos
1:07
Developing targeted therapies for urachal and non-urachal adenocarcinoma
Antonio Cigliola • 26 Jan 2024
5:26
Molecular and immunologic insights in prostate cancer based on site of metastasis
Umang Swami • 25 Jan 2024
1:21
Genomic differences between urachal and non-urachal bladder adenocarcinoma
Antonio Cigliola • 26 Jan 2024
1:41
Current and emerging applications for ctDNA analysis in prostate cancer
Dalia Kaakour • 26 Jan 2024
View All Videos
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:57
PROs in advanced cisplatin-ineligible UC: first-line EV ± pembrolizumab
Jonathan Rosenberg • 7 Apr 2024
1:05
HRQoL in patients with previously treated advanced urothelial carcinoma from EV-301: EV vs chemo
Jonathan Rosenberg • 7 Apr 2024
1:01
Sacituzumab govitecan and other ADCs in prostate cancer
Umang Swami • 25 Jan 2024
View All Videos
1:26
[68Ga]Ga-DPI-4452, a novel CA IX-targeting peptide, in metastatic ccRCC
Michael Hofman • 25 Jan 2024
1:20
Advances in theranostics for prostate cancer
Michael Hofman • 25 Jan 2024
2:01
The emerging role of PET tracers in managing renal cell carcinoma
Michael Hofman • 25 Jan 2024
1:00
Improving prostate cancer awareness for earlier diagnosis in Asian populations
Deborah Mukherji • 22 Nov 2023
View All Videos
1:09
What role does FDG-PET have in managing bladder cancer?
Antonio Cigliola • 26 Jan 2024
1:06
Predicting pelvic lymph node involvement in MIBC with FDG-PET
Antonio Cigliola • 26 Jan 2024
1:39
SECuRE: 67Cu-SAR-bisPSMA, a novel PSMA theranostic, in mCRPC
Geoffrey Johnson • 25 Jan 2024
1:20
Updates in PSMA radiopharmaceutical therapies for prostate cancer
Benjamin Lowentritt • 25 Jan 2024
View All Videos

Conferences

AACR 2024
ASCO GU 2024
ESMO 2023
ASCO 2023
EAU 2023
AACR 2023
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
View All Videos
2:23
Which patients with prostate cancer benefit from radiotherapy and hormonal therapy?
Alan Dal Pra • 31 Jan 2024
3:47
Salvage radiotherapy in biochemically recurrent prostate cancer
Alan Dal Pra • 31 Jan 2024
1:07
Developing targeted therapies for urachal and non-urachal adenocarcinoma
Antonio Cigliola • 26 Jan 2024
1:01
Sacituzumab govitecan and other ADCs in prostate cancer
Umang Swami • 25 Jan 2024
View All Videos
7:29
Neoadjuvant and adjuvant strategies in localized MIBC: current approaches and future directions
Daniele Raggi • 8 Dec 2023
7:17
Cognitive function in prostate cancer: assessment, impact, and management
Daniele Raggi • 8 Dec 2023
1:55
Assessing cognitive impairment: crucial considerations in treatment planning
Daniele Raggi • 8 Dec 2023
3:00
Insights from PROSCA/BLADDR 2023: multidisciplinary discussions and educational components
Rob Jones • 6 Dec 2023
View All Videos
3:50
Advancing prostate cancer diagnosis with PSMA PET: opportunities and cautions
Ravi Madan • 12 Jun 2023
1:11
The optimal sequence of ADCs and other therapies in advanced and metastatic urothelial cancer
Shilpa Gupta • 3 Jun 2023
1:02
The role of EV and pembrolizumab in the urothelial carcinoma treatment landscape
Shilpa Gupta • 3 Jun 2023
6:02
EV-103: EV + pembrolizumab as a promising first-line option for urothelial carcinoma
Shilpa Gupta • 3 Jun 2023
View All Videos
1:52
Enhancing the efficacy of immunotherapy in prostate cancer
Scott Tagawa • 16 Apr 2023
2:25
Phase I trial of ARX517, an anti-PSMA ADC, in mCRPC
Scott Tagawa • 16 Apr 2023
2:05
What role will ADCs play in the prostate cancer treatment landscape?
Scott Tagawa • 16 Apr 2023
1:06
Unanswered questions and unmet needs in prostate cancer
John Michael Bryant • 17 Apr 2023
View All Videos

The GU Cancer Channel on VJOncology is supported by Exelixis

These supporters have no influence over the production of the content.

The content of VJOncology is intended for healthcare professionals